Without a JV Partner for LymPro, the revenue guida
Post# of 30028
Posted On: 09/02/2014 12:53:16 PM
Without a JV Partner for LymPro, the revenue guidance and bridge test data are more important than ever in getting our pps above .20 cents!
The bridge test is mainly designed to show version 2 is better than version 1. But I hope they are able to present the data in a way that excites non-scientific shareholders and the market. Our pps got up to .193 cents prior to the July 31st Conference just in anticipation of the promised data. Gerald must deliver good data in September for our pps to rise enough to make up listing possible this year.
It sounds like Gerald doesn't want to talk today on the CC about any of the business arrangements concerning LymPro (Potential JV Partner, Diagnostic Spin-off, etc) He says he is "contractually prohibited." I understand that. But, for him to ask us for a billion more authorized shares with our stock trading below .13 cents and no JV Partner for Lympro and no MANF orphan approval yet....he may be getting the cart before the horse.
Maybe the shareholder meeting on Sept. 22nd needs to be postponed until Gerald has hit more of his milestone promises so we can all make an informed decision?
If tonight's CC only deals in very broad generalities for revenue guidance, and no bridge test data is discussed....and no business developments regarding LymPro can be discussed,...the pps won't ignite.
The bridge test is mainly designed to show version 2 is better than version 1. But I hope they are able to present the data in a way that excites non-scientific shareholders and the market. Our pps got up to .193 cents prior to the July 31st Conference just in anticipation of the promised data. Gerald must deliver good data in September for our pps to rise enough to make up listing possible this year.
It sounds like Gerald doesn't want to talk today on the CC about any of the business arrangements concerning LymPro (Potential JV Partner, Diagnostic Spin-off, etc) He says he is "contractually prohibited." I understand that. But, for him to ask us for a billion more authorized shares with our stock trading below .13 cents and no JV Partner for Lympro and no MANF orphan approval yet....he may be getting the cart before the horse.
Maybe the shareholder meeting on Sept. 22nd needs to be postponed until Gerald has hit more of his milestone promises so we can all make an informed decision?
If tonight's CC only deals in very broad generalities for revenue guidance, and no bridge test data is discussed....and no business developments regarding LymPro can be discussed,...the pps won't ignite.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼